
    
      The study is a single-centre, double-blind, randomized, placebo-controlled, parallel group
      phase I study with healthy male subjects receiving ascending single oral oral doses of Px-102
      to assess the safety and tolerability, pharmacokinetics and pharmacodynamics.
    
  